Trial · NCT02111850
Adverse events770
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 770
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase I Dose Escalation Arm 1, Dose Level 1 - 1 X 10^7 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase I Dose Escalation Arm 1, Dose Level 2 - 3 X 10^7 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase I Dose Escalation Arm 1 Dose Level 3 - 1 X 10^8 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase I Dose Escalation Arm 1, Dose Level 4 - 3 X 10^8 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase I Dose Escalation Arm 1, Dose Level 5 - 1 X 10^9 Cells + Interleukin-2 | 1 | 2 | 1 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase I Dose Escalation Arm 1, Dose Level 6 - 3 X 10^9 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase I Dose Escalation Arm 1, Dose Level 7 - 1 X 10^10 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase I Dose Escalation Arm 1, Dose Level 8 - 3 X 10^10 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase I Dose Escalation Arm 1, Dose Level 9 - 1 X 10^11 Cells + Interleukin-2 | 0 | 6 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase 2 Arm 2, Cohort 1- Maximum Tolerated Dose + Interleukin-2 Other | 0 | 5 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Phase 2 Arm 2, Cohort 2 - Maximum Tolerated Dose + Interleukin-2 Melanoma | 0 | 1 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Escalation Arm 1, Dose Level 1 - 1 X 10^7 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Escalation Arm 1, Dose Level 2 - 3 X 10^7 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Escalation Arm 1 Dose Level 3 - 1 X 10^8 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Escalation Arm 1, Dose Level 4 - 3 X 10^8 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Escalation Arm 1, Dose Level 5 - 1 X 10^9 Cells + Interleukin-2 | 0 | 2 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Escalation Arm 1, Dose Level 6 - 3 X 10^9 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Escalation Arm 1, Dose Level 7 - 1 X 10^10 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Escalation Arm 1, Dose Level 8 - 3 X 10^10 Cells + Interleukin-2 | 0 | 1 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase I Dose Escalation Arm 1, Dose Level 9 - 1 X 10^11 Cells + Interleukin-2 | 0 | 6 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02111850/events